Alfasigma secures 150 mln eur EIB loan for rare diseases and specialty care

Brussels – The European Investment Bank (EIB) has signed a EUR 150 million loan agreement with Alfasigma, a global pharmaceutical company founded in Italy, whose products are present in over 100 markets worldwide.

The agreement, announced today by Gelsomina Vigliotti EIB Vice-President and Tatiana Simonelli, Chief Financial Officer of Alfasigma, will support the development of breakthrough therapies in the areas of rare diseases and specialty care, the bank stated. The EIB financing aims to support Alfasigma’s R&D activities over the three-year period from 2025 to 2027, focusing on new treatments in gastroenterology and hepatology, vascular medicine, and rheumatology. 

The agreement will also help “accelerate the translation of scientific advances into patient-centered solutions, aiming to address unmet needs and deliver high-impact health outcomes,” according to the statement.

The operation is part of the EIB’s strategy to bolster competitiveness and innovation in the European healthcare sector as well as to create highly skilled jobs.